Correlation Between Kunyue Development and Energenesis Biomedical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Kunyue Development and Energenesis Biomedical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kunyue Development and Energenesis Biomedical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kunyue Development Co and Energenesis Biomedical Co, you can compare the effects of market volatilities on Kunyue Development and Energenesis Biomedical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kunyue Development with a short position of Energenesis Biomedical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kunyue Development and Energenesis Biomedical.

Diversification Opportunities for Kunyue Development and Energenesis Biomedical

0.61
  Correlation Coefficient

Poor diversification

The 3 months correlation between Kunyue and Energenesis is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Kunyue Development Co and Energenesis Biomedical Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Energenesis Biomedical and Kunyue Development is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kunyue Development Co are associated (or correlated) with Energenesis Biomedical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Energenesis Biomedical has no effect on the direction of Kunyue Development i.e., Kunyue Development and Energenesis Biomedical go up and down completely randomly.

Pair Corralation between Kunyue Development and Energenesis Biomedical

Assuming the 90 days trading horizon Kunyue Development Co is expected to generate 1.15 times more return on investment than Energenesis Biomedical. However, Kunyue Development is 1.15 times more volatile than Energenesis Biomedical Co. It trades about 0.19 of its potential returns per unit of risk. Energenesis Biomedical Co is currently generating about -0.01 per unit of risk. If you would invest  3,480  in Kunyue Development Co on September 26, 2024 and sell it today you would earn a total of  675.00  from holding Kunyue Development Co or generate 19.4% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Kunyue Development Co  vs.  Energenesis Biomedical Co

 Performance 
       Timeline  
Kunyue Development 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Kunyue Development Co are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, Kunyue Development is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.
Energenesis Biomedical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Energenesis Biomedical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Energenesis Biomedical is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Kunyue Development and Energenesis Biomedical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Kunyue Development and Energenesis Biomedical

The main advantage of trading using opposite Kunyue Development and Energenesis Biomedical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kunyue Development position performs unexpectedly, Energenesis Biomedical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Energenesis Biomedical will offset losses from the drop in Energenesis Biomedical's long position.
The idea behind Kunyue Development Co and Energenesis Biomedical Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance